{"id":643,"date":"2020-11-12T10:28:06","date_gmt":"2020-11-12T10:28:06","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=643"},"modified":"2020-11-30T12:14:39","modified_gmt":"2020-11-30T12:14:39","slug":"10-nov-2020-remdesivir-associated-with-a-significant-mortality-benefit","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/10-nov-2020-remdesivir-associated-with-a-significant-mortality-benefit\/","title":{"rendered":"(10 Nov 2020) Remdesivir- associated with a significant mortality benefit"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis<\/p>\n<p class=\"\">https:\/\/www.medrxiv.org\/content\/10.1101\/2020.11.05.20226373v1.full.pdf<\/p>\n<p class=\"\">Of 350 patients treated with remdesivir, 346 were included for the final analysis (males: 270 [78.0%]; median [range] age: 60 [24-94] years). Overall, 243 (70.2%) patients had \u22651 comorbidity; 109 (31.5%) patients had moderate disease, 237 (68.5%) had severe disease, and 50 (14.5%) patients required mechanical ventilation. Of the 346 patients, 76 (22.0%) patients died (moderate: 3 [2.8%], severe: 73 [30.8%]). In the subset of mechanically ventilated patients, 43 (86.0%) died. All-cause mortality was significantly lower in patients with SORT interval \u22649 days (n = 260) compared with those with SORT interval &gt;9 days (n = 86; 18.1% vs 33.7%; P = .004). The odds of death were significantly lower in patients with SORT interval \u22649 days vs &gt;9 days (odds ratio = 0.44; 95% CI, 0.25-0.76; P = .004). Adverse events (transaminitis \u22655 times upper limit of normal or estimated glomerular filtration rate &lt;30ml\/min) leading to drug discontinuation were seen in 4 (1.1%) patients.&nbsp; In this large series of moderate-to-severe COVID-19, initiation of remdesivir \u22649 days from symptom-onset was associated with a significant mortality benefit.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis https:\/\/www.medrxiv.org\/content\/10.1101\/2020.11.05.20226373v1.full.pdf Of 350 patients treated with remdesivir, 346 were included for the final analysis (males: 270 [78.0%]; median [range] age:&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/10-nov-2020-remdesivir-associated-with-a-significant-mortality-benefit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(10 Nov 2020) Remdesivir- associated with a significant mortality benefit&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,5],"tags":[25],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/643"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=643"}],"version-history":[{"count":2,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/643\/revisions"}],"predecessor-version":[{"id":690,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/643\/revisions\/690"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}